Silence Therapeutics plc

NASDAQ:SLN

Biotechnology

Healthcare
$19.82 +2.81%

+$0.19 today

Market cap
$936.18M
Beta
1.48
P/E (TTM)
-3.9
EPS (TTM)
-$1.80
52W Low $4.19High $8.40

Volume 1.47M

Average 0.31M

SLN Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Silence Therapeutics plcNASDAQ: SLN

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses turns positive

Q1 FY2026 other income / expenses was $88.85K, compared with -$156.54K a year earlier. Trailing-twelve-month other income / expenses was $1.43M. Over 3 fiscal years it compounded at -50.1% a year.

Context

  • Other income / expenses amounted to 206.1% of revenue in FY2025, up 162.5 pp from a year earlier.
  • Other income / expenses increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly other income / expenses holds near $88.85K or moves back toward the trailing-twelve-month quarterly average of $357.52K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$88.85K-87.1% QoQ
Last fiscal yearDec 2025
$1.15M-93.9% YoY
LTMMar 2026
$1.43M— YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+156.8%——
1 year-93.9%——
3-year CAGR-50.1%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

Mixed currencies · from the income statement

Latest · FY2025
1.15M USD
Year-over-year change
—

Other Income / Expenses vs competitors

How SLN compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Other income / expenses amounts to 155.2% of revenue for SLN, versus a peer median of 3.7%.
SLN Competitors
Other Income / Expenses for SLN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$65.43M USD+239.3%—3.0%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$21.61M USD+11.8%-76.4%2.3%
WVEWave Life Sciences Ltd.LTM Mar 2026$13.29M USD-1.0%+91.1%18.5%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$10.54M USD-22.0%—23.2%
BNTCBenitec Biopharma Inc.LTM Mar 2026$5.05M USD+38.6%——
SLNSilence Therapeutics plcLTM Mar 2026$1.43M USD—-50.1%155.2%
PRQRProQR Therapeutics N.V.LTM Mar 2026€840.44K EUR-70.3%+16.3%6.3%
RNAAtrium Therapeutics, Inc.FY2025-$12K USD——0.1%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026-$16.74M USD+64.2%—3.7%
ADRXADARx Pharmaceuticals, Inc.—— ———
Peer median (excluding SLN) —+11.8%+16.3%3.7%

Competitors are the stored peer set for SLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · GBP
FY2025
Dec 2025 · USD
Revenue12.42M17.65M25.38M43.26M559K
Cost of Revenue7.46M10.97M10.32M11.81M215K
Gross Profit4.96M6.68M15.06M31.45M344K
Gross Margin39.9%37.8%59.3%72.7%61.5%
Research & Development30.77M35.5M44.03M67.88M67.75M
Selling, General & Admin20.01M20.94M20.64M26.88M22.34M
Operating Expenses50.77M56.44M64.66M94.77M90.1M
Depreciation & Amortization427K485.86K498K593K555K
EBITDA(45.42M)(39.94M)(49.78M)(48.99M)(88.05M)
EBITDA Margin-365.9%-226.2%-196.2%-113.2%-15750.6%
Operating Income(45.81M)(49.76M)(49.6M)(63.32M)(89.75M)
Operating Margin-369.0%-281.9%-195.5%-146.4%-16056.0%
Interest Income10K226K1.45M4.47M3.48M
Interest Expense8K47K34K00
Other Income / Expenses(42K)9.29M(706K)18.86M1.15M
Income Before Tax(45.86M)(40.47M)(50.31M)(44.46M)(88.6M)
Pre-Tax Margin-369.4%-229.3%-198.3%-102.8%-15849.9%
Income Tax Expense(6.45M)560.85K(7.04M)845K11K
Net Income(39.41M)(41.03M)(43.27M)(45.31M)(88.61M)
Net Margin-317.4%-232.4%-170.5%-104.7%-15851.9%
EPS (Basic)(1.35)(3.78)(3.48)(2.37)(1.89)
EPS (Diluted)(1.35)(3.78)(3.48)(2.37)(1.89)
Weighted Avg Shares29.65M10.73M12.36M15.42M47.23M
Weighted Avg Shares (Diluted)29.65M10.73M12.36M15.42M47.23M

Silence Therapeutics plc

NASDAQ:SLN

Intrinsic Alpha fair value

Locked

Current Price

$19.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.